高血压及RAS阻滞剂与肾脏ACE2表达无关
该研究基于多达436例患者的肾脏转录组数据,分析高血压、代谢共病及降压药与肾脏ACE2表达的关系,并在其他人体组织和实验模型中进行验证。结果显示肾脏ACE2表达与高血压或常见RAS抑制药物无关,ACE2表达随年龄在肺和肾脏中增加,且与肾功能生化指标正相关。结论提示高血压及降压治疗不太可能改变人肾脏中SARS-CoV-2关键进入受体的表达。
要点
- 高血压及常见RAS抑制药物与肾脏ACE2表达无关联。
- 肺和肾脏ACE2表达随年龄增加,可能与SARS-CoV-2感染风险相关。
- 肾脏ACE2表达与肾功能生化指标正相关,提示其可能具有肾脏保护作用。
核心结论
- 高血压及降压治疗不太可能改变人肾脏中SARS-CoV-2关键进入受体ACE2的表达。
- 在无SARS-CoV-2感染情况下,肾脏ACE2最可能具有肾脏保护作用。
- 肺和肾脏中ACE2表达随年龄增加,可能与SARS-CoV-2感染风险相关。
研究设计与样本
- 利用多达436例患者的肾脏转录组RNA测序数据,分析高血压、代谢共病及降压药与肾脏ACE2表达的关系。
- 在其他人体组织和/或受控实验模型中验证部分关键观察。
主要发现
- 人肺和肾脏中ACE2表达随年龄增加。
- 肾脏ACE2表达与高血压或常见RAS抑制药物类型均无关联。
- 肾脏ACE2丰度与肾功能生化指标正相关。
- ACE2共表达分析显示肾脏健康与疾病相关基因强烈富集。
临床怎么用
- 高血压患者无需因担心ACE2表达改变而停用RAS抑制药物。
- 年龄增长伴随肺和肾脏ACE2表达增加,或需关注老年人群SARS-CoV-2感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Angiotensin-converting enzyme 2 (ACE2) is the cellular entry point for severe acute respiratory syndrome coronavirus (SARS-CoV-2)-the cause of coronavirus disease 2019 (COVID-19). However, the effect of renin-angiotensin system (RAS)-inhibition on ACE2 expression in human tissues of key relevance to blood pressure regulation and COVID-19 infection has not previously been reported. METHODS AND RESULTS: We examined how hypertension, its major metabolic co-phenotypes, and antihypertensive medications relate to ACE2 renal expression using information from up to 436 patients whose kidney transcriptomes were characterized by RNA-sequencing. We further validated some of the key observations in other human tissues and/or a controlled experimental model. Our data reveal increasing expression of ACE2 with age in both human lungs and the kidney. We show no association between renal expression of ACE2 and either hypertension or common types of RAS inhibiting drugs. We demonstrate that renal abundance of ACE2 is positively associated with a biochemical index of kidney function and show a strong enrichment for genes responsible for kidney health and disease in ACE2 co-expression analysis. CONCLUSION: Our results indicate that neither hypertension nor antihypertensive treatment is likely to alter the expression of the key entry receptor for SARS-CoV-2 in the human kidney. Our data further suggest that in the absence of SARS-CoV-2 infection, kidney ACE2 is most likely nephro-protective but the age-related increase in its expression within lungs and kidneys may be relevant to the risk of SARS-CoV-2 infection.
引用
- Jiang X, Eales JM, Scannali D, et al. Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney. Eur Heart J. 2020. PMID: 33206176. doi:10.1093/eurheartj/ehaa794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。